Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CA19-9

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: CA19-9. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-005790-60 Sponsor Protocol Number: CL-SBP-101-04 Start Date*: 2022-08-05
    Sponsor Name:Panbela Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Temporarily Halted) IT (Prematurely Ended) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004552-64 Sponsor Protocol Number: 131016 Start Date*: 2017-07-03
    Sponsor Name:Center for Digestive Diseases, Karolinska University Hospital
    Full Title: MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical tr...
    Medical condition: Primary or recurrent inoperable pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003080-26 Sponsor Protocol Number: CASSANDRA Start Date*: 2020-10-14
    Sponsor Name:FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE)
    Full Title: A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC).
    Medical condition: Patients with pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003550-88 Sponsor Protocol Number: TMV-018-101 Start Date*: 2020-07-03
    Sponsor Name:Themis Bioscience GmbH
    Full Title: Full title of the trial: A Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intra-tumoral application of TMV-018 in combination with 5...
    Medical condition: Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10062240 Tumor vaccine therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004968-56 Sponsor Protocol Number: OCTO_063 Start Date*: 2015-11-20
    Sponsor Name:University of Oxford Clinical Trials & Research Governance
    Full Title: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
    Medical condition: Locally advanced non-metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004981-52 Sponsor Protocol Number: GEMNABCCC-001 Start Date*: 2016-09-28
    Sponsor Name:University Hospital Essen
    Full Title: Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study The NACHO trial (GEMNABCCC-001)
    Medical condition: unresecable, metastatic or recurrent cholangiocarcinoma (intrahepatic cholangiocellular carcinoma, bile duct cancer, gall bladder carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001695-42 Sponsor Protocol Number: CAN04CLIN004 Start Date*: 2021-07-27
    Sponsor Name:Cantargia AB
    Full Title: A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000905-38 Sponsor Protocol Number: PCYC-1137-CA Start Date*: 2015-12-17
    Sponsor Name:Pharmacyclics LLC
    Full Title: A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in c...
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002957-42 Sponsor Protocol Number: EMR200592-001 Start Date*: 2013-08-06
    Sponsor Name:Merck KGaA
    Full Title: A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjec...
    Medical condition: Locally advanced unresectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Completed) PL (Completed) FI (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003086-28 Sponsor Protocol Number: MM-398-07-02-03 Start Date*: 2016-07-27
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: A randomized, open-label, Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic...
    Medical condition: Previously Untreated, Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003553-27 Sponsor Protocol Number: WF10-05-001 Start Date*: 2005-11-28
    Sponsor Name:DIMETHAID AG
    Full Title: A SINGLE CENTRE, OPEN LABEL, PHASE II CLINICAL STUDY OF THE ADJUNCTIVE BENEFIT OF WF10 TO STANDARD CAPECITABINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE PANCREATIC CANCER
    Medical condition: UNRESECTABLE PANCREATIC CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001394-15 Sponsor Protocol Number: WCTU012 Start Date*: 2008-10-14
    Sponsor Name:Cardiff University
    Full Title: A multi-centre randomised phase II study of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy (CRT) for locally advanced non-metastatic pancreatic cancer
    Medical condition: Advanced localised non-metastatic pancreatic cancer (LANPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001332-35 Sponsor Protocol Number: AX-CL-PANC-PI-0006859 Start Date*: 2017-03-20
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer
    Medical condition: Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003596-27 Sponsor Protocol Number: BIBABRAX Start Date*: 2015-02-23
    Sponsor Name:Asociación de Oncología Médica del Hospital de Cruces (ASONMEC)
    Full Title: A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003310-24 Sponsor Protocol Number: UDCAPSCSURV Start Date*: 2015-10-09
    Sponsor Name:Sahlgrenska Academy
    Full Title: A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified Treatment with Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy ...
    Medical condition: Primary sclerosing cholangitis with or without concomitant inflammatory bowel disease included in an unlimited surveillance program for hepatobiliary and colorectal malignancy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002040-78 Sponsor Protocol Number: D8151C00001 Start Date*: 2021-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid...
    Medical condition: Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002949-42 Sponsor Protocol Number: PACT-29 Start Date*: 2020-11-27
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing a germ line BRCA or other DNA Defects Repair (DDR) mutations.
    Medical condition: Patients affected by metastatic pancreatic adenocarcinoma (PDAC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007476-42 Sponsor Protocol Number: CP4126-201 Start Date*: 2009-01-09
    Sponsor Name:Clavis Pharma ASA
    Full Title: A phase II study of CP-4126 in patients with advanced pancreatic cancer
    Medical condition: Pancreatic Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005386-35 Sponsor Protocol Number: GI-4000-02 Start Date*: 2008-10-07
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant...
    Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 13:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA